← All organizations
Highest phase reached
Phase 2
First clinical trial
Jan 1, 2003Last known activity
Nov 15, 2017
Defunct as of Jan 1, 2008
Timeline
2000s
- Jun 1, 2000
Erimos Pharmaceuticals— Founded
- Jan 1, 2008
Erimos Pharmaceuticals— Defunct
Drugs by trial phase (1 distinct, 6 trials)
Phase 2 (1 own, 0 via acquisition)
Indications
Studied for
- Carcinoma in Situ
- Cervical Intraepithelial Neoplasia
- Glioma
- Head and Neck Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Leukemia, T-Cell
- Myelodysplastic Syndromes
- Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recent trials (9)
- NCT02575794CollaboratorPhase 1Nov 15, 2017
- NCT00664677Lead sponsorPhase 1Aug 1, 2007
- NCT00664677Study directorPhase 1Aug 1, 2007
- NCT00664586Lead sponsorPhase 1May 1, 2007
- NCT00664586Study directorPhase 1May 1, 2007
- NCT00259818OfficialPhase 1Dec 1, 2005
- NCT00259818Lead sponsorPhase 1Dec 1, 2005
- NCT00154089Lead sponsorPhase 1/Phase 2Nov 1, 2004
- NCT00057512Lead sponsorPhase 1Jan 1, 2003
Details
- Founded
- Houston, TX, US Jun 1, 2000
- Last known activity
- Nov 15, 2017